
RxSight (RXST) Stock Forecast & Price Target
RxSight (RXST) Analyst Ratings
Bulls say
RxSight Inc has reported a gross margin of 71.6%, reflecting a substantial year-over-year increase of 980 basis points and exceeding consensus expectations. The company achieved Light Adjustable Lens (LAL) revenue of $28.5 million, marking a 60% increase, while Light Delivery Device (LDD) revenue reached $10.7 million with a 7% rise, both in alignment with consensus figures. Strong performance indicators such as increased LAL utilization alongside a growing LDD installed base suggest potential for sustained double-digit growth and further margin improvements in the future.
Bears say
RxSight Inc. has demonstrated a notable deceleration in LAL utilization, which fell to 9% year-over-year in the fourth quarter of 2024, a significant drop from the 17%-22% growth range observed in the previous five quarters. The company faces challenges in the U.S. intraocular lens (IOL) market, where growth has likely stagnated or declined, potentially influenced by weakened end market conditions and increased competition. Additionally, revised earnings per share estimates for 2025 and 2026 reflect a more pessimistic outlook, indicating potential struggles with profitability and market adoption of their technology.
This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.
RxSight (RXST) Analyst Forecast & Price Prediction
Start investing in RxSight (RXST)
Order type
Buy in
Order amount
Est. shares
0 shares